Agenda

Course Description

  • WHO: This course provides pharmacists, pharmacy technicians and members of academia, industry and government with the skills necessary to develop and implement a collaborative testing program for influenza, Group A streptococcus, HIV, hepatitis C and COVID19.
  • WHY: There is a recognized need for pharmacists and pharmacy technicians to collaboratively improve patient access to care through the use of point-of-care tests.
  • HOW: The course’s 20 hours of continuing education (16 hours of home study and 4 hours of live training) will cover information on the targeted disease state, the physical assessment of a patient presenting to a pharmacist, point-of-care tests and how to establish a point-of-care testing service.
  • WHEN: Please visit the upcoming trainings webpage for more information.

Program Course

Home-Study Modules (16 Hours)

  • Identify opportunities for pharmacists to use point-of-care tests (POCT) and treatment and if needed paired with a statewide protocol (SWP) or collaborative practice agreement (CPA) in pharmacy settings.
  • Describe the role of pharmacists and feedback from the general public and public health representatives on expanded roles for pharmacists.
  • How pharmacy-based testing and treatment has evolved.
  • Summarize the Clinical Laboratory Improvement Amendments (CLIA) as they pertain to pharmacy point-of-care testing (POCT).
  • Identify the basic requirements for performing Clinical Laboratory Improvement Amendments (CLIA) waived testing.
  • Identify at least three good laboratory practices for preparing the laboratory or testing site to produce high quality test results.
  • Select at least two good laboratory practices that ensure the right sample type is obtained from the correct patient.
  • Identify at least two good laboratory practices for testing.
  • Identify at least two good laboratory practices for recording and reporting results.
  • Describe the process of obtaining a CLIA certificate of waiver.
  • List elements of Good Laboratory Practices recommended for CLIA-waived testing sites.
  • Identify useful websites offering guidance on CLIA-waived testing.
  • Outline an approach to find each state’s pharmacy practice acts.
  • Summarize the seven criteria used to assign a Clinical Laboratory Improvement Amendments (CLIA) category for point- of-care tests (POCT).
  • Describe common technology and the evolution of technology use for POCTs.
  • Identify and discuss the function of the components of a lateral flow assay.
  • Differentiate between competitive and sandwich lateral flow assays.
  • List the ideal characteristics of a POCT.
  • Define the terms used to describe test performance, including sensitivity, specificity, PPV (Positive Predictive Value) and NPV (Negative Predictive Value).
  • Describe factors that can influence test performance.
  • Explain how test performance influences interpretation of test results.

Respiratory infections (e.g., Influenza, Respiratory Syncytial Virus, Coronavirus); Pharyngitis; Conjunctivitis

  • Understand the epidemiology of the diseases/conditions listed above.
  • Identify the signs and symptoms associated with the diseases/conditions listed above.
  • Outline the process of screening patients to increase the probability that a patient may or may not have one of the diseases/conditions listed above.
  • Construct a treatment plan for a patient identified with the diseases/conditions listed above.
  • Discuss the complications associated with the diseases/conditions listed above.
  • Provide a patient case, identify characteristics of individuals who may be candidates for point-of-care testing (POCT) in a community pharmacy setting versus those who require referral to a physician/provider or acute care setting.

Explain the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states:

  • Sexually Transmitted Infections (e.g., syphilis, chlamydia, and gonorrhea)
  • HIV – PrEP and PEP
  • Hepatitis C Virus
  • Infectious mononucleosis
  • Lyme Disease
  • Helicobacter pylori
  • Discuss characteristics of a condition that support developing chronic disease management services in a pharmacy.
  • Identify CLIA-waived point-of-care tests that could be utilized for a chronic disease management service in a pharmacy.
  • Discuss the value and limitations of various physical assessment procedures, including temperature, pulse, blood pressure, respiratory rate, pulse oximetry and physical inspection.
  • Describe and show the procedures for conducting a systematic physical assessment and identify normal and critical findings.
  • Interpret physical assessment data and recognize limitations of the data.

Toggle Content

  • Describe the basic process of specimen collection for point-of-care testing (POCT).
  • Identify a patient specimen that would be appropriate for a Clinical Laboratory Improvement Amendments (CLIA)-waived POCT.
  • Describe the technique involved for the specimen collection types discussed.
  • Describe the elements required for an effective, patient focused point-of-care testing (POCT) service.
  • Discuss issues related to billing insurers for POCT a by pharmacists.
  • Describe considerations and preparations needed prior to performing waived testing.
  • Define and summarize antimicrobial stewardship.
  • Identify ways that pharmacists can practice stewardship and reduce antimicrobial resistance.
  • Summarize how point-of-care testing (POCT) can reduce unnecessary antibiotic use and contribute to a pharmacy’s stewardship program.
  • Understand the role and responsibilities of state and local health departments, especially as they relate to disease surveillance and reporting.
  • Identify steps to develop partnerships with state and local health departments around point-of-care testing (POCT).
  • Summarize the benefits and value of partnering with state and local health departments.
  • Describe the impact regulatory changes have had on pharmacy-based point-of-care testing.
  • Identify changes in healthcare delivery that have the potential to impact pharmacy-based point-of-care testing.
  • Identify opportunities for expanding patient-centered services in the pharmacy setting, using point-of-care testing.
  • Discuss the value and limitations of patient reported symptoms, medical history, and drug allergies.
  • Describe and perform the following physical assessments, when appropriate to patient care: Blood Pressure, Pulse, Respiratory Rate, Oxygenation, Cervical Lymph Node Inspection.
  • Describe and perform the following specimen collections used in point-of-care testing: Throat swab, Nasal swab.
  • Apply this information to patient-specific cases based on common pharmacy-based patient interactions.